Business
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
Presentation to Discuss Advancing Universal Targeted Radiotherapies FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:
About this update from Cellectar Biosciences, Inc.
[{"type":"text","content":"Presentation to Discuss Advancing Universal Targeted Radiotherapies\nFLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar’s chief operating officer (COO), will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany. Cellectar at the Targeted Radiopharmaceuticals Summit Europe Presentation Title: Advancing Universal Targeted Radiotherapies: Unleashing the Potential of Alpha & Beta Particles for Solid & Hematologic MalignanciesDate/Time: Thursday, December 7, 2023 at 11:30 a.m. CETSession: Delving into Isotopes to Maximise the Efficacy of Your TRPLocation: Berlin Marriott Hotel “This conference unites global radiopharmaceutical innovators and leaders to complete a deep dive into the successes, new scientific breakthroughs, and complexities of radiopharmaceuticals. We look forward to discussing the versatility of Cellectar’s proprietary PLE delivery platform, which targets unique changes in the cancerous cell membranes, presenting an opportunity to be a universal targeting agent,” said Jarrod Longcor, Cellectar’s COO. “Additionally, I am honored to be chosen to co-chair the Radiopharmaceuticals Summit Europe Conference in support of the advancement of radiopharmaceuticals as a rapidly emerging and important therapeutic class.” About Cellectar Biosciences, Inc.Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. For more informati...